BNP as a marker of the heart failure in the treatment of imatinib mesylate.
Since its introduction 6 years ago, imatinib mesylate, a selective tyrosine kinase inhibitor, has been a phenomenon in treating chronic myelogenous leukemia (CML) with remarkably superior cytogenetic and molecular response rates at all stages of CML followed by longer progression free survival. Despite its extraordinarily high efficacy, adverse effects of imatinib mesylate such as edema, liver toxicity and fluid retention syndromes have been reported. Here we, for the first time, report development of heart failure in patients on imatinib mesylate medication and the possibility of brain natriuretic peptide (BNP) as a potential diagnostic (or predicting) marker for heart failure. Since plasma BNP levels in the two patients were exceptionally high, we then explored the possibility of genetic association of BNP with the development of heart failure to find no positive association.
Park
Yeon Hee
YH
Department of Medical Oncology, Korea Institute of Radiological and Medical Sciences, Seoul 130-706, South Korea.
Park
Hae Jeong
HJ
Kim
Bong-Seog
BS
Ha
Eunyoung
E
Jung
Kyung Hee
KH
Yoon
Seo Hyun
SH
Yim
Sung Vin
SV
Chung
Joo-Ho
JH
D000328:Adult; D000368:Aged; D000483:Alleles; D001483:Base Sequence; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D004252:DNA Mutational Analysis; D003967:Diarrhea / Q000139:chemically induced; D004487:Edema / Q000139:chemically induced; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy / Q000235:genetics; D005787:Gene Frequency; D005838:Genotype; D006333:Heart Failure / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood* / Q000235:genetics; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D001549:Benzamides; D014408:Biomarkers, Tumor; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D020097:Natriuretic Peptide, Brain; D000068877:Imatinib Mesylate